Breakthrough Blood Test Developed for Bowel Cancer Diagnosis
By LabMedica International staff writers Posted on 18 Feb 2015 |
A new blood test for bowel cancer has been developed which could save thousands of lives by spotting the disease at the earliest possible opportunity and the simple check will pick up on antibodies in the blood, produced as the body reacts to the onset of bowel cancer.
The identification of these very specific biomarkers will allow for a test which is more sensitive and accurate than existing screening. This means it will not only save lives, through earlier, more reliable and faster diagnosis, but because it is a simple blood test, it is hoped it will encourage more people to come forward for bowel cancer screening.
Bowel cancer is the third most common cancer in the UK, with almost 40,000 people diagnosed each year. The UK NHS Bowel Screening Program has been rolled out to check those between the ages of 60–69, (up to 74 in England) thought to be at high risk. This screening involves testing traces of blood found in stool samples. Drawbacks associated with this method, known as Fecal Occult Blood Test (FOBt), include low sensitivity, which means early stage disease is not detected in a rapid or reliable way. In addition, the nature of the sample required for these tests has resulted in worryingly low levels of patient uptake. The new blood test will do away with the need for FOBt and will prevent unnecessary and costly colonoscopies for people without the disease.
Collaboration between the UK biotech firm Randox Laboratories Ltd., (Crumlin, UK) and Biomedical Diagnostics Institute (BDI; Dublin City University, Ireland) promises that the new test will be a significant breakthrough in the diagnosis of bowel cancer and could be available for widespread use by the end of next year. The new test will be implemented on Randox's proprietary Biochip Array Technology detection platform.
Conor Burke, PhD, Associate Director of the BDI commented, “This project is an excellent example of the translational research agenda of the BDI and its commitment to the realization of commercial and societal impact through innovation in diagnostics. One of our primary goals is the creation of value for indigenous Irish diagnostics companies through our research and we look forward to working with Randox on realizing the significant commercial and healthcare-related potential of this screening test.”
Related Links:
Randox Laboratories Ltd.
Biomedical Diagnostics Institute
The identification of these very specific biomarkers will allow for a test which is more sensitive and accurate than existing screening. This means it will not only save lives, through earlier, more reliable and faster diagnosis, but because it is a simple blood test, it is hoped it will encourage more people to come forward for bowel cancer screening.
Bowel cancer is the third most common cancer in the UK, with almost 40,000 people diagnosed each year. The UK NHS Bowel Screening Program has been rolled out to check those between the ages of 60–69, (up to 74 in England) thought to be at high risk. This screening involves testing traces of blood found in stool samples. Drawbacks associated with this method, known as Fecal Occult Blood Test (FOBt), include low sensitivity, which means early stage disease is not detected in a rapid or reliable way. In addition, the nature of the sample required for these tests has resulted in worryingly low levels of patient uptake. The new blood test will do away with the need for FOBt and will prevent unnecessary and costly colonoscopies for people without the disease.
Collaboration between the UK biotech firm Randox Laboratories Ltd., (Crumlin, UK) and Biomedical Diagnostics Institute (BDI; Dublin City University, Ireland) promises that the new test will be a significant breakthrough in the diagnosis of bowel cancer and could be available for widespread use by the end of next year. The new test will be implemented on Randox's proprietary Biochip Array Technology detection platform.
Conor Burke, PhD, Associate Director of the BDI commented, “This project is an excellent example of the translational research agenda of the BDI and its commitment to the realization of commercial and societal impact through innovation in diagnostics. One of our primary goals is the creation of value for indigenous Irish diagnostics companies through our research and we look forward to working with Randox on realizing the significant commercial and healthcare-related potential of this screening test.”
Related Links:
Randox Laboratories Ltd.
Biomedical Diagnostics Institute
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities